{"id":"bms-986165","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4596392","moleculeType":"Small molecule","molecularWeight":"422.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug blocks the common p40 subunit shared by IL-12 and IL-23 cytokines, which are key drivers of Th1 and Th17 cell differentiation and inflammatory responses. By inhibiting both pathways simultaneously, BMS-986165 suppresses pathogenic immune responses implicated in autoimmune and inflammatory conditions. This dual inhibition provides broader immunomodulation compared to selective IL-23 inhibitors alone.","oneSentence":"BMS-986165 is a selective inhibitor of the interleukin-12 and interleukin-23 (IL-12/IL-23) p40 subunit that reduces inflammatory signaling in immune-mediated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:03.824Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT06979453","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-03","conditions":"Plaque Psoriasis","enrollment":366},{"nctId":"NCT03920267","phase":"PHASE2","title":"Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-03-26","conditions":"Systemic Lupus Erythematosus","enrollment":261},{"nctId":"NCT07335796","phase":"PHASE2","title":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-09","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06869551","phase":"PHASE3","title":"A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-03-13","conditions":"Juvenile Psoriatic Arthritis","enrollment":60},{"nctId":"NCT05946941","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-09-11","conditions":"Sjögren's Syndrome","enrollment":774},{"nctId":"NCT06875960","phase":"PHASE4","title":"A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-27","conditions":"Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)","enrollment":35},{"nctId":"NCT06444399","phase":"PHASE2","title":"Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-07-29","conditions":"Pityriasis Rubra Pilaris","enrollment":12},{"nctId":"NCT07326813","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-01-13","conditions":"Plaque Psoriasis","enrollment":477},{"nctId":"NCT06476834","phase":"PHASE4","title":"A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-06-24","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT05620407","phase":"PHASE3","title":"A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-12","conditions":"Systemic Lupus Erythematosus","enrollment":513},{"nctId":"NCT05478499","phase":"PHASE4","title":"Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-10-06","conditions":"Psoriasis","enrollment":154},{"nctId":"NCT04908202","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-13","conditions":"Psoriatic Arthritis","enrollment":670},{"nctId":"NCT04036435","phase":"PHASE3","title":"Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-12","conditions":"Psoriasis","enrollment":1466},{"nctId":"NCT04772079","phase":"PHASE3","title":"A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-03-23","conditions":"Plaque Psoriasis","enrollment":153},{"nctId":"NCT04857034","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-12","conditions":"Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous","enrollment":74},{"nctId":"NCT05701995","phase":"PHASE4","title":"A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-31","conditions":"Psoriasis","enrollment":180},{"nctId":"NCT06042920","phase":"PHASE4","title":"A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2023-10-09","conditions":"Palmoplantar Psoriasis, Genital Psoriasis","enrollment":130},{"nctId":"NCT06566768","phase":"PHASE1","title":"Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-07","conditions":"Healthy Participants","enrollment":52},{"nctId":"NCT04908189","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-15","conditions":"Psoriatic Arthritis","enrollment":729},{"nctId":"NCT06091956","phase":"PHASE2","title":"A Study of Deucravacitinib to Treat LPP and FFA","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2023-11-07","conditions":"Lichen Planopilaris","enrollment":12},{"nctId":"NCT05556265","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-11-08","conditions":"Alopecia Areata","enrollment":94},{"nctId":"NCT05997277","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-11-30","conditions":"Hidradenitis Suppurativa","enrollment":7},{"nctId":"NCT06851871","phase":"PHASE1","title":"A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-01-23","conditions":"Healthy Participants","enrollment":26},{"nctId":"NCT04877990","phase":"PHASE2","title":"A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-05-07","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":67},{"nctId":"NCT04613518","phase":"PHASE2","title":"A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-03-15","conditions":"Colitis, Ulcerative","enrollment":38},{"nctId":"NCT03599622","phase":"PHASE2","title":"An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-07-16","conditions":"Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis","enrollment":239},{"nctId":"NCT03934216","phase":"PHASE2","title":"Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-07-01","conditions":"Ulcerative Colitis","enrollment":131},{"nctId":"NCT04167462","phase":"PHASE3","title":"An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-25","conditions":"Psoriasis","enrollment":220},{"nctId":"NCT03624127","phase":"PHASE3","title":"Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-08-07","conditions":"Psoriasis","enrollment":666},{"nctId":"NCT03611751","phase":"PHASE3","title":"An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-07-26","conditions":"Psoriasis","enrollment":1020},{"nctId":"NCT03252587","phase":"PHASE2","title":"An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-09-21","conditions":"Systemic Lupus Erythematosus","enrollment":363},{"nctId":"NCT03924427","phase":"PHASE3","title":"An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-10","conditions":"Psoriasis","enrollment":74},{"nctId":"NCT03943147","phase":"PHASE2","title":"An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2019-07-15","conditions":"Lupus Nephritis","enrollment":16},{"nctId":"NCT05065762","phase":"","title":"Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-10-01","conditions":"Psoriasis","enrollment":232},{"nctId":"NCT04949269","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-20","conditions":"Healthy Participants","enrollment":61},{"nctId":"NCT03881059","phase":"PHASE2","title":"Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-01","conditions":"Active Psoriatic Arthritis","enrollment":203},{"nctId":"NCT03930602","phase":"PHASE1","title":"Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-05-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT04671953","phase":"PHASE1","title":"Effect of BMS-986165 on the Blood Levels of Metformin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-12-18","conditions":"Healthy Participants","enrollment":36},{"nctId":"NCT04305899","phase":"PHASE1","title":"A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-08-31","conditions":"Healthy Participants","enrollment":40},{"nctId":"NCT04536961","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-09-10","conditions":"Healthy Volunteers","enrollment":56},{"nctId":"NCT03890770","phase":"PHASE1","title":"A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-04","conditions":"Renal Impairment, Healthy Volunteer","enrollment":44},{"nctId":"NCT03739788","phase":"PHASE1","title":"An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-12-05","conditions":"Healthy Participants","enrollment":8},{"nctId":"NCT04065932","phase":"PHASE1","title":"A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-22","conditions":"Lupus","enrollment":33},{"nctId":"NCT02931838","phase":"PHASE2","title":"Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11-15","conditions":"Psoriasis","enrollment":268},{"nctId":"NCT03979248","phase":"PHASE1","title":"A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-05-16","conditions":"Healthy","enrollment":21},{"nctId":"NCT03890809","phase":"PHASE1","title":"An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-02-26","conditions":"Liver Dysfunction, Healthy Volunteers","enrollment":32},{"nctId":"NCT04113668","phase":"PHASE1","title":"The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-10-01","conditions":"Healthy Participants","enrollment":48},{"nctId":"NCT04086719","phase":"PHASE1","title":"An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-12","conditions":"Healthy Male Volunteers","enrollment":16},{"nctId":"NCT04055506","phase":"PHASE1","title":"A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-14","conditions":"Healthy Participants","enrollment":16},{"nctId":"NCT03956953","phase":"PHASE1","title":"Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-04","conditions":"Autoimmune Diseases","enrollment":135},{"nctId":"NCT04209699","phase":"PHASE1","title":"A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-12-27","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT04249284","phase":"PHASE1","title":"Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-02-06","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT03262727","phase":"PHASE1","title":"The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-09-01","conditions":"Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis","enrollment":49},{"nctId":"NCT03419910","phase":"PHASE1","title":"An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-05","conditions":"Psoriasis","enrollment":54},{"nctId":"NCT03402087","phase":"PHASE1","title":"A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-01-08","conditions":"Lupus, Psoriatic Arthritis","enrollment":30},{"nctId":"NCT03254784","phase":"PHASE1","title":"A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-09-13","conditions":"Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis","enrollment":49},{"nctId":"NCT03541564","phase":"PHASE1","title":"An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-30","conditions":"Systemic Lupus Erythematosus, Healthy Participants","enrollment":84},{"nctId":"NCT03873415","phase":"PHASE1","title":"Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-01-25","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT03751228","phase":"PHASE1","title":"A Taste Assessment of BMS-986165 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-11","conditions":"Healthy Participants","enrollment":9},{"nctId":"NCT03660436","phase":"PHASE1","title":"An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-08-14","conditions":"Healthy Participants","enrollment":131},{"nctId":"NCT03004768","phase":"PHASE1","title":"Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-26","conditions":"Psoriasis","enrollment":6},{"nctId":"NCT03044873","phase":"PHASE1","title":"Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-02-02","conditions":"Autoimmune Diseases, Inflammatory Diseases","enrollment":20},{"nctId":"NCT02534636","phase":"PHASE1","title":"Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10","conditions":"Healthy Subjects","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Deucravacitinib"],"phase":"marketed","status":"active","brandName":"BMS-986165","genericName":"BMS-986165","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986165 is a selective inhibitor of the interleukin-12 and interleukin-23 (IL-12/IL-23) p40 subunit that reduces inflammatory signaling in immune-mediated diseases. Used for Psoriasis, Psoriatic arthritis, Crohn's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":34,"withResults":11},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}